These drugs include histone deacetylase inhibitors, hypomethylating agents, PI3-kinase pathway inhibitors, dihydrofolate reductase inhibitors, and JAK/STAT pathway inhibitors, each showing varying efficacy across PTCL subtypes. The gene discussed is SOAT1; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.